Indans - Therapeutic use
Research News and Information

Sunday, November 22, 2009

Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease.

6 Sep 2009 OBJECTIVE: To evaluate the influence of the single nucleotide polymorphism rs1080985 in the cytochrome P450 2D6 (CYP2D6) gene on the efficacy of donepezil in patients with mild to moderate Alzheimer disease (AD). METHODS: This was a multicenter, ... Read more...

Successful use of donepezil in treatment of cognitive impairment caused by maintenance electroconvulsive therapy: a case report.

30 Aug 2009 Cognitive deficits are commonly associated with maintenance electroconvulsive therapy (ECT). Treatment of these cognitive deficits is important but difficult. Cholinergic pathways are involved in these side effects, and donepezil, a cholinesterase ... Read more...

The effects of counseling spouse caregivers of people with Alzheimer disease taking donepezil and of country of residence on rates of admission to nursing homes and mortality.

30 Aug 2009 OBJECTIVE: Does psychosocial intervention for caregivers whose spouses with Alzheimer disease (AD) are taking donepezil delay nursing home (NH) placement or death of patients? DESIGN: Randomized controlled trial with 2 years of active treatment and ... Read more...

Latest indexed articles for 'Indans - Therapeutic use'

These are the very latest articles for this heading:

• Donepezil treatment of patients with MCI: a 48-week randomized, placebo- controlled trial. Nov 2009
• Santhera licenses novel dyskinesia therapy to Biovail. 29 Sep 2009
• Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. 6 Sep 2009
• Successful use of donepezil in treatment of cognitive impairment caused by maintenance electroconvulsive therapy: a case report. 30 Aug 2009
• The effects of counseling spouse caregivers of people with Alzheimer disease taking donepezil and of country of residence on rates of admission to nursing homes and mortality. 30 Aug 2009
• Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial). 30 Aug 2009
• Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial. 10 Aug 2009
• The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. 30 Jul 2009
• Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil. 30 Jul 2009
• How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist. 30 Jul 2009
• DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. 22 Jul 2009
• Recovery of cognitive dysfunction in a case of delayed encephalopathy of carbon monoxide poisoning after treatment with donepezil hydrochloride. 29 Jun 2009
• Response to "Results, rhetoric, and randomized trials: the case of donepezil". 29 Jun 2009
• Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. 17 Jun 2009
• Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine. 3 Jun 2009
• Donepezil in severe Alzheimer's disease. 30 May 2009
• Treatment of Alzheimer's disease in the long-term-care setting. 13 May 2009
• Synthesis and bioactivity of substituted indan-1-ylideneaminoguanidine derivatives. 3 May 2009
• Donepezil in the treatment of patients with Alzheimer's disease. 29 Apr 2009
• Top cited papers in international psychogeriatrics: 3. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. 14 Apr 2009

See a longer list of these articles.

Technical information about 'Indans'

Definition: Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES.

Registry Number: 0

Descriptor UI: D007189

Alternative terms: Indans; Indanones;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D02.455.426.559.847.486.487; D04.615.486.487;

Online Note: search INDENES 1966-74

History Note: 91(75)63-67; was see under INDENES 1975-90; was heading 1963-67